On Friday November 2, the second full day of SDPA’s 16th Annual Fall Dermatology Conference Dr. Misha Rosenbach spoke about What’s New in Biologics. Many of the topics he discussed included off label use since indications are still limited. His specialty is granulomatous and neutrophilic diseases and he has used biologic therapy for such conditions …
Treating psoriasis with a systemic biologic therapy is increasingly the standard course of treatment, but little is known about how these therapies affect the elderly. Elderly patients are frequently excluded from biological clinical trials and simply described as a high-risk group for adverse events. This has led to a lack of information about safety and …
Biologic agents used to treat chronic inflammatory diseases are complex and often expensive medications. More affordable versions of biologic agents, known as a “biosimilars” are starting to hit the marketplace, but clinicians may be unsure about their characteristics and use, and possibly more reluctant to prescribe them. A recent review article sought to provide the …